title: Endophthalmitis after intravitreal treatment with ranibizumab.
authors.affiliation: Servicio de Microbiología y Medicina Preventiva, Complejo Hospitalario Universitario de Canarias, San Cristóbal de La Laguna, Santa Cruz de Tenerife, España. Electronic address: kohanrocio@gmail.com.
authors.forename: Rocío
authors.initials: R
authors.lastname: Kohan
authors.affiliation: Servicio de Microbiología y Medicina Preventiva, Complejo Hospitalario Universitario de Canarias, San Cristóbal de La Laguna, Santa Cruz de Tenerife, España.
authors.forename: María Antonia
authors.initials: MA
authors.lastname: Miguel
authors.affiliation: Servicio de Oftalmología, Complejo Hospitalario Universitario de Canarias, San Cristóbal de La Laguna, Santa Cruz de Tenerife, España.
authors.forename: Luis
authors.initials: L
authors.lastname: Cordovés
authors.affiliation: Servicio de Microbiología y Medicina Preventiva, Complejo Hospitalario Universitario de Canarias, San Cristóbal de La Laguna, Santa Cruz de Tenerife, España.
authors.forename: María
authors.initials: M
authors.lastname: Lecuona-Fernández
mesh_terms: D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004203:Disinfection; D009877:Endophthalmitis / Q000188:drug therapy / Q000209:etiology* / Q000382:microbiology / Q000601:surgery; D015353:Eye Enucleation; D006801:Humans; D058449:Intravitreal Injections / Q000009:adverse effects*; D008268:Macular Degeneration / Q000188:drug therapy; D008297:Male; D011008:Pneumococcal Infections / Q000188:drug therapy / Q000209:etiology* / Q000382:microbiology / Q000601:surgery; D011241:Prednisone / Q000627:therapeutic use; D000069579:Ranibizumab / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D065288:Serogroup; D013296:Streptococcus pneumoniae / Q000145:classification / Q000302:isolation & purification; D014821:Vitrectomy; D014822:Vitreous Body / Q000382:microbiology
chemical_list: D000900:Anti-Bacterial Agents; D011241:Prednisone; D000069579:Ranibizumab